Ayala Pharmaceuticals, Inc.
已退市CIK 1100397fmd_10XGT4Y3WDEH9G7JMETRNGTFF3制造业 · 医药制剂模板: 标准
覆盖范围: 2003年1月01日 至 2023年12月31日，共 64 个期间
| 项目 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | 4 | 12 | 6 | 21 | 0 | 3 | 0 | – | 0 |
| 营业成本 | – | – | – | – | – | – | – | – | 1 | 0 |
| 毛利润 | – | – | – | – | – | – | – | – | 0 | 0 |
| 研发费用 | 24 | 49 | 71 | 57 | 27 | 16 | 11 | – | 28 | 24 |
| 营业费用合计 | 49 | 80 | 110 | 76 | 39 | 27 | 22 | 20 | – | – |
| 营业利润 | (49) | (76) | (98) | (70) | (18) | (26) | (19) | – | (38) | (36) |
| 利息费用 | – | – | – | – | – | – | – | – | – | – |
| 利息及投资收益 | – | – | – | – | – | – | – | – | – | – |
| 其他营业外收入（支出） | (0) | (0) | (0) | (0) | (0) | – | (0) | – | 0 | (16) |
| 税前利润 | (49) | (76) | (98) | (66) | (17) | (26) | (18) | – | (37) | (52) |
| 所得税费用 | (2) | (3) | (4) | 0 | 0 | 0 | 0 | – | 1 | (4) |
| 持续经营净利润 | (47) | (74) | (93) | (67) | (17) | (26) | (18) | – | (38) | (48) |
| 净利润 | (47) | (74) | (93) | (67) | (17) | (26) | (18) | – | (38) | (48) |
| 归属于普通股股东的净利润 | – | – | – | – | – | – | (18) | – | (38) | (48) |